Anticancer research · 2026
Nitric Oxide-Releasing Gemcitabine Derivatives Induce Apoptotic Cancer Cell Death.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kubo Natsumi, Takasaki Kaho, Uchibori Shotaro, Murase Hirotaka, Imoto Shuhei, Tsukigawa Kenji, Tokuno Masahiro, Otagiri Masaki, Yamasaki Keishi, Ueno-Shuto Keiko, Nishi Koji
Аннотация
BACKGROUND/AIM: Poor tumor perfusion can limit drug delivery to solid tumors and reduce the therapeutic efficacy of anticancer agents. Nitric oxide (NO) is a bioactive molecule that can modulate tumor vasculature. In this study, we synthesized two NO-releasing gemcitabine derivatives, GEM-NPB and GEM-NO, to explore whether NO-releasing modification preserves the anticancer activity of gemcitabine while providing NO-donor properties.
MATERIALS AND METHODS: The NO-donor properties of GEM-NPB and GEM-NO were evaluated by measuring NOx formation and compared with those of the previously developed NO donor NPB. The antiproliferative effects of gemcitabine, GEM-NPB, GEM-NO, and NPB were examined in C26 cancer cells using an MTS assay. Cell death was assessed by an Annexin V assay. Apoptotic signaling was evaluated by western blotting for poly(ADP-ribose) polymerase (PARP) cleavage. The effects of these compounds were also examined using C26 spheroids.
RESULTS: GEM-NPB and GEM-NO showed time-dependent NOx formation, indicating that both compounds retained NO-donor properties. In C26 cells, both derivatives inhibited cell proliferation in a concentration-dependent manner, although their effects were weaker than those of gemcitabine. The Annexin V assay showed that GEM-NPB and GEM-NO induced cell death; however, at 50 μM, GEM-NPB induced significantly less cell death than gemcitabine. Gemcitabine, GEM-NPB and GEM-NO induced PARP cleavage, whereas NPB alone did not. In spheroids, gemcitabine, GEM-NPB, and GEM-NO caused surface disruption suggestive of cell damage or cell death, whereas NPB alone did not induce apparent surface disruption.
CONCLUSION: GEM-NPB and GEM-NO retain gemcitabine-like apoptosis-inducing activity while acquiring NO-donor properties. These findings provide a basis for the further development of NO-releasing gemcitabine derivatives as candidate anticancer agents for poorly perfused solid tumors.
MATERIALS AND METHODS: The NO-donor properties of GEM-NPB and GEM-NO were evaluated by measuring NOx formation and compared with those of the previously developed NO donor NPB. The antiproliferative effects of gemcitabine, GEM-NPB, GEM-NO, and NPB were examined in C26 cancer cells using an MTS assay. Cell death was assessed by an Annexin V assay. Apoptotic signaling was evaluated by western blotting for poly(ADP-ribose) polymerase (PARP) cleavage. The effects of these compounds were also examined using C26 spheroids.
RESULTS: GEM-NPB and GEM-NO showed time-dependent NOx formation, indicating that both compounds retained NO-donor properties. In C26 cells, both derivatives inhibited cell proliferation in a concentration-dependent manner, although their effects were weaker than those of gemcitabine. The Annexin V assay showed that GEM-NPB and GEM-NO induced cell death; however, at 50 μM, GEM-NPB induced significantly less cell death than gemcitabine. Gemcitabine, GEM-NPB and GEM-NO induced PARP cleavage, whereas NPB alone did not. In spheroids, gemcitabine, GEM-NPB, and GEM-NO caused surface disruption suggestive of cell damage or cell death, whereas NPB alone did not induce apparent surface disruption.
CONCLUSION: GEM-NPB and GEM-NO retain gemcitabine-like apoptosis-inducing activity while acquiring NO-donor properties. These findings provide a basis for the further development of NO-releasing gemcitabine derivatives as candidate anticancer agents for poorly perfused solid tumors.